Physician

William Patrick Fusselman, MD

According to 2025 Medicare claims, William Fusselman, MD (NPI: 1659356228) practices hematology/oncology in the Cedar Rapids, IA market, with the plurality of this provider's patient population coming from Linn, IA. This provider's primary affiliated billing organization is PHYSICIANS' CLINIC OF IOWA, PC (NPI: 1821075599; TIN: 421462899) and primary practice location at 52403-2414. Fusselman is affiliated with the UnityPoint Accountable Care, L.C. (ACO ID: A5170), Aledade 155 National MSSP (ACO ID: A5358), and Main Street Rural Health Willow ACO LLC (ACO ID: A5404), participating under the MSSP model.

Fusselman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 544 traditional Medicare patients, billed 171,258 HCPCS/CPT codes, and received $3,059,689 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,598 prescription claims across 259 beneficiaries totaling $3,896,758 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 11 claims. Open Payments data shows 11 records totaling $27,188. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,408,298 and ending at $3,896,758. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	620	156,289	$2,016,677
2016	634	214,436	$2,321,986
2017	620	203,326	$2,589,962
2018	575	172,101	$2,784,982
2019	591	221,426	$3,268,508
2020	478	235,058	$3,012,914
2021	486	219,381	$2,203,882
2022	563	174,422	$2,316,340
2023	587	204,324	$3,419,003
2024	544	171,258	$3,059,689

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	202	1,256	$1,408,298
2016	247	1,824	$2,963,423
2017	221	1,388	$1,854,023
2018	191	1,071	$1,996,280
2019	193	927	$1,578,446
2020	178	804	$874,115
2021	185	833	$1,199,966
2022	207	980	$1,942,343
2023	236	1,192	$2,846,198
2024	259	1,598	$3,896,758

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	84	$10,721
2016	N/R	136	$10,533
2017	N/R	68	$2,828
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$278
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	223	698	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	345	551	$63
80053	Blood test, comprehensive group of blood chemicals	425	1,409	$10
36415	Insertion of needle into vein for collection of blood sample	412	1,014	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	422	1,476	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	30	840	$636,172
Lenalidomide	Lenalidomide	41	1,148	$628,238
Imbruvica	Ibrutinib	30	840	$483,041
Pomalyst	Pomalidomide	16	448	$364,729
Cabometyx	Cabozantinib S-Malate	12	360	$311,927

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$217	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$26,971	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for William Patrick Fusselman, MD?

Tedicare shows public-source Medicare data for William Patrick Fusselman, MD (NPI 1659356228), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does William Patrick Fusselman, MD have ACO affiliation data?

William Patrick Fusselman, MD is shown with ACO affiliation data for UnityPoint Accountable Care, L.C. (MSSP, ACO ID A5170), Aledade 155 National MSSP (MSSP, ACO ID A5358), and Main Street Rural Health Willow ACO LLC (MSSP, ACO ID A5404).

What billing organization is linked to William Patrick Fusselman, MD?

William Patrick Fusselman, MD is linked to PHYSICIANS' CLINIC OF IOWA, PC (billing NPI 1821075599) in the available physician profile data.

Does William Patrick Fusselman, MD have Open Payments data?

William Patrick Fusselman, MD has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.